Table 3:

Performance of twelve participants for the prediction of metastatic disease in patients with PPGL, before vs after provision of the SDHB mutation status

	AUCs (CI)		Paired comparisons
	Dataset without SDHB status	Dataset with SDHB status
Selected ENS model	0·942 (0·894-0·969)	0·940 (0·885-0·968)	-
Participants
1M	0·815 (0·778-0·853)	0·761 (0·723-0·799)	0·1020
2L	0·764 (0·723-0·805)	0·787 (0·747-0·828)	0·2350
3L	0·752 (0·710-0·794)	0·766 (0·723-0·810)	0·1090
4M	0·735 (0·689-0·781)	0·812 (0·781-0·854)	0·0001 (↑)
5M	0·731 (0·687-0·776)	0·793 (0·749-0·836)	0·1570
6L	0·717 (0·670-0·764)	0·794 (0·750-0·838)	0·0001 (↑)
7M	0·717 (0·670-0·763)	0·758 (0·711-0·805)	0·1420
8L	0·685 (0·639-0·731)	0·667 (0·617-0·717)	0·1980
9M	0·680 (0·642-0·719)	0·725 (0·685-0·764)	0·1800
10M	0·651 (0·609-0·694)	0·733 (0·684-0·782)	0·1720
11L	0·644 (0·601-0·687)	0·762 (0·720-0·802)	0·0001 (↑)
12M	0·630 (0·582-0·677)	0·730 (0·684-0·776)	0·0001 (↑)

ENS: Ensemble Tree Classifier; M: clinical care specialists with experience on the field of PPGL more than ten years; L: clinical care specialists with experience on the field of PPGL between five to ten years; AUC: area under the Roc Curve; CI: 95% confidence intervals